Developer docs
API playgroundTry for free, no card

Search company profiles

Onxeo

Full company profile

uuid000633w

Namestring
Onxeo
Legal namestring
Valerio Therapeutics
Websiteurl
onxeo.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Onxeo, now commercially operating as Valerio Therapeutics, is a France-domiciled, publicly traded clinical-stage biotechnology company focused on precision-guided therapeutics for oncology and other complex diseases with high unmet medical need. The company is built around a proprietary V-Body platform based on two fully synthetic single-domain antibody (sdAb) libraries — one derived from a human VH and one from a fully humanized VHH — yielding ultra-small antibodies of approximately 15 kDa that are engineered for deep tissue penetration and highly precise therapeutic delivery. The V-Body platform is integrated with a proprietary chemistry stack that provides novel linker and payload technologies for drug-conjugate development, and target identification is supported by advanced predictive models and antibody engineering aimed at high specificity and affinity.

Commercially, the company does not sell products directly. Its business model is partnership-driven: candidates are advanced from preclinical research through clinical proof-of-concept in indications with limited treatment options, and then monetized through co-development arrangements, out-licensing deals, and R&D collaborations with other biopharmaceutical companies. Customers are therefore enterprise biopharma partners rather than end patients, and pricing/contract terms are not publicly disclosed. The company employs 11-50 people and is listed on Euronext Growth Paris under ticker ALONX, having previously operated under the Onxeo name.

Between October 2025 and mid-2026 the company executed a dense strategic transformation: a capital increase with cancellation of preferential subscription rights (October 2025), completion of a merger with its subsidiary Valour Bio (December 2025), appointment of a new CEO (Gilles Besin, June 2026), relocation of headquarters and laboratories to The Hive by Kadans facility in Villejuif (March 2026), and the May 2026 launch of InVimmune, a wholly-owned subsidiary focused on differentiated in vivo cell therapy. It also signed a binding term-sheet for an exclusive license collaboration with a seed-stage biotech in May 2026. The strategic posture is best characterized as a platform company rebuilding its operating model around the V-Body and chemistry stacks while extending into adjacent modalities via spin-out vehicles.

Short descriptiontext

Valerio Therapeutics (formerly Onxeo) is a French clinical-stage biotechnology company developing precision-guided therapeutics for complex diseases using its proprietary synthetic single-domain antibody V-Body platform and integrated chemistry stack, monetizing candidates via out-licensing and R&D partnerships with other biopharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVillejuif, France
HQ citystring
Villejuif
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision-guided therapeutics, single-domain antibody platform, drug conjugate development, oncology biopharmaceuticals, antibody-drug conjugates
Industry1 code
PRIMARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Precision-Guided Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic partnerships and licensing
TypeLicensing Royalties
Description

Valerio Therapeutics advances therapeutic candidates to key development milestones before forging strategic partnerships. Revenue is generated through co-development arrangements, out-licensing deals, and R&D collaborations to maximize the potential of innovations.

valeriotx.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Valerio Therapeutics (formerly Onxeo) develops precision-guided therapeutics through two integrated proprietary platforms: the V-Body Platform, based on ultra-small (~15 kDa) fully synthetic single-domain antibodies enabling deep tissue penetration and precise therapeutic delivery, and the Fully Integrated Chemistry Platform for drug conjugate development. The company advances candidates from preclinical research to clinical proof of concept in indications with high unmet medical need, then commercializes via strategic partnerships, co-development, and out-licensing.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Valerio Therapeutics (formerly Onxeo) is a biotechnology company pioneering next-generation precision-guided therapeutics. The company operates two integrated proprietary platforms: the V-Body Platform (based on ultra-small single-domain antibodies of ~15 kDa for deep tissue penetration and precise therapeutic delivery) and the Fully Integrated Chemistry Platform (leveraging cutting-edge linker and payload technologies). These platforms work together to enable drug conjugate development targeting complex and underserved diseases. The company also launched InVimmune as a new subsidiary focused on in vivo cell therapy approaches. Valerio Therapeutics advances therapeutic candidates through preclinical research to clinical proof of concept in indications with high unmet medical needs, with a business model focused on strategic partnerships, co-development, and out-licensing.

Product and service3 records
1V-Body Platform
CategoryTherapeutic platform technology
Description

Proprietary technology platform based on two fully synthetic single-domain antibody (sdAb) libraries derived from human VH and fully humanized VHH; the ultra-small (~15 kDa) sdAb format enables deep tissue penetration and highly precise therapeutic delivery for superior efficacy and target engagement in complex and underserved diseases.

2Fully Integrated Chemistry Platform
CategoryTherapeutic platform technology
Description

Proprietary chemistry platform integrated with the V-Body platform for drug conjugate development, leveraging cutting-edge linker and payload technologies to enable precise and efficient targeted delivery of therapeutics.

3InVimmune
CategoryIn vivo cell therapy subsidiary
Description

Newly launched wholly owned subsidiary company dedicated to developing differentiated in vivo cell therapy approaches, expanding the therapeutic pipeline beyond traditional conjugate therapeutics.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Valerio Therapeutics announced a binding term-sheet for collaboration and exclusive license with a seed-stage biotech company on May 18, 2026. This partnership represents a strategic collaboration to advance therapeutic development through exclusive licensing arrangements.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-04
Description

Valerio Therapeutics announced the launch of InVimmune, a new company dedicated to developing differentiated in vivo cell therapy approaches on May 4, 2026. This represents the company's expansion into novel therapeutic modalities through strategic venture creation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-12
Description

Completion of merger between Valerio Therapeutics and its subsidiary Valour Bio on December 12, 2025, following the proposed merger announced on October 31, 2025. This consolidation streamlines operations and strengthens the company's therapeutic development capabilities.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage biotech built on llama-derived VHH single-domain antibodies; the closest comparable to Valerio's V-Body sdAb platform, with multiple approved and late-stage autoimmune programs.

TypeDirect peer
Description

Develops DARPins and other small designed binding proteins for oncology; comparable to Valerio's use of ultra-small, fully synthetic single-domain scaffolds for targeted therapeutics.

3Harbour BioMed
TypeDirect peer
Description

Operates a single-domain antibody (HBM7008 and others) platform spanning immuno-oncology and immunology; directly comparable in using sdAb-based therapeutics.

TypeDirect peer
Description

Antibody platform company (Duobody, Hexabody) with multiple approved and partnered oncology assets; comparable partner-driven business model and focus on next-generation antibody engineering.

TypeDirect peer
Description

Clinical-stage developer of antibody-drug conjugates and immunotherapies for difficult-to-treat tumors; comparable ADC pipeline and oncology focus.

TypeEmerging player
Description

Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs); comparable as a small-cap ADC developer with platform technology.

TypeBroad incumbent
Description

Pioneer in ADC technology (now part of AbbVie following the 2024 acquisition); broader incumbent with approved ADCs and an established payload/linker franchise.

TypeBroad incumbent
Description

Co-developer of Enhertu and Datroway with AstraZeneca; large incumbent in the ADC space that Valerio's chemistry platform ultimately competes with or partners alongside.

TypeBroad incumbent
Description

Acquired Ablynx, the originator of Nanobody/VHH therapeutics; the established large-pharma owner of the most clinically validated sdAb franchise (e.g., Cablivi).

TypeEmerging player
Description

Clinical-stage gene and cell therapy company working on allogeneic and in vivo cell therapy approaches; relevant peer for Valerio's newly launched InVimmune subsidiary.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Onxeo

Precision-Guided Biopharmaceuticalsonxeo.com

Valerio Therapeutics (formerly Onxeo) is a French clinical-stage biotechnology company developing precision-guided therapeutics for complex diseases using its proprietary synthetic single-domain antibody V-Body platform and integrated chemistry stack, monetizing candidates via out-licensing and R&D partnerships with other biopharmaceutical companies.

What Onxeo does

Onxeo, now commercially operating as Valerio Therapeutics, is a France-domiciled, publicly traded clinical-stage biotechnology company focused on precision-guided therapeutics for oncology and other complex diseases with high unmet medical need. The company is built around a proprietary V-Body platform based on two fully synthetic single-domain antibody (sdAb) libraries — one derived from a human VH and one from a fully humanized VHH — yielding ultra-small antibodies of approximately 15 kDa that are engineered for deep tissue penetration and highly precise therapeutic delivery. The V-Body platform is integrated with a proprietary chemistry stack that provides novel linker and payload technologies for drug-conjugate development, and target identification is supported by advanced predictive models and antibody engineering aimed at high specificity and affinity.

Commercially, the company does not sell products directly. Its business model is partnership-driven: candidates are advanced from preclinical research through clinical proof-of-concept in indications with limited treatment options, and then monetized through co-development arrangements, out-licensing deals, and R&D collaborations with other biopharmaceutical companies. Customers are therefore enterprise biopharma partners rather than end patients, and pricing/contract terms are not publicly disclosed. The company employs 11-50 people and is listed on Euronext Growth Paris under ticker ALONX, having previously operated under the Onxeo name.

Between October 2025 and mid-2026 the company executed a dense strategic transformation: a capital increase with cancellation of preferential subscription rights (October 2025), completion of a merger with its subsidiary Valour Bio (December 2025), appointment of a new CEO (Gilles Besin, June 2026), relocation of headquarters and laboratories to The Hive by Kadans facility in Villejuif (March 2026), and the May 2026 launch of InVimmune, a wholly-owned subsidiary focused on differentiated in vivo cell therapy. It also signed a binding term-sheet for an exclusive license collaboration with a seed-stage biotech in May 2026. The strategic posture is best characterized as a platform company rebuilding its operating model around the V-Body and chemistry stacks while extending into adjacent modalities via spin-out vehicles.

Onxeo firmographics

Firmographics
Name
Onxeo
Legal name
Valerio Therapeutics
Website
https://onxeo.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Valerio Therapeutics (formerly Onxeo) is a French clinical-stage biotechnology company developing precision-guided therapeutics for complex diseases using its proprietary synthetic single-domain antibody V-Body platform and integrated chemistry stack, monetizing candidates via out-licensing and R&D partnerships with other biopharmaceutical companies.
Ownership category
akta.pro rank

Onxeo industry classification

Industry
Product category
Precision-Guided Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision-guided therapeutics
  • Single-domain antibody platform
  • Drug conjugate development
  • Oncology biopharmaceuticals
  • Antibody-drug conjugates

Where Onxeo is headquartered

Location

Headquarters

HQ city
Villejuif
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Onxeo business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Strategic partnerships and licensing: Valerio Therapeutics advances therapeutic candidates to key development milestones before forging strategic partnerships. Revenue is generated through co-development arrangements, out-licensing deals, and R&D collaborations to maximize the potential of innovations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Onxeo product offering

Product offering

Core offering

Valerio Therapeutics (formerly Onxeo) develops precision-guided therapeutics through two integrated proprietary platforms: the V-Body Platform, based on ultra-small (~15 kDa) fully synthetic single-domain antibodies enabling deep tissue penetration and precise therapeutic delivery, and the Fully Integrated Chemistry Platform for drug conjugate development. The company advances candidates from preclinical research to clinical proof of concept in indications with high unmet medical need, then commercializes via strategic partnerships, co-development, and out-licensing.

Product overview

Valerio Therapeutics (formerly Onxeo) is a biotechnology company pioneering next-generation precision-guided therapeutics. The company operates two integrated proprietary platforms: the V-Body Platform (based on ultra-small single-domain antibodies of ~15 kDa for deep tissue penetration and precise therapeutic delivery) and the Fully Integrated Chemistry Platform (leveraging cutting-edge linker and payload technologies). These platforms work together to enable drug conjugate development targeting complex and underserved diseases. The company also launched InVimmune as a new subsidiary focused on in vivo cell therapy approaches. Valerio Therapeutics advances therapeutic candidates through preclinical research to clinical proof of concept in indications with high unmet medical needs, with a business model focused on strategic partnerships, co-development, and out-licensing.

Differentiator

Problem solved

Functional benefit

Products and services

  • V-Body Platform Proprietary technology platform based on two fully synthetic single-domain antibody (sdAb) libraries derived from human VH and fully humanized VHH; the ultra-small (~15 kDa) sdAb format enables deep tissue penetration and highly precise therapeutic delivery for superior efficacy and target engagement in complex and underserved diseases.
  • Fully Integrated Chemistry Platform Proprietary chemistry platform integrated with the V-Body platform for drug conjugate development, leveraging cutting-edge linker and payload technologies to enable precise and efficient targeted delivery of therapeutics.
  • InVimmune Newly launched wholly owned subsidiary company dedicated to developing differentiated in vivo cell therapy approaches, expanding the therapeutic pipeline beyond traditional conjugate therapeutics.

Companies that use Onxeo

Customer profile

Segments1 record

Ideal customer profiles1 record

Onxeo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Onxeo partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Seed-stage biotech companycoreStrategic or Co-development Partner · 18 May 2026Valerio Therapeutics announced a binding term-sheet for collaboration and exclusive license with a seed-stage biotech company on May 18, 2026. This partnership represents a strategic collaboration to advance therapeutic development through exclusive licensing arrangements.
  • InVimmunecoreStrategic or Co-development Partner · 4 May 2026Valerio Therapeutics announced the launch of InVimmune, a new company dedicated to developing differentiated in vivo cell therapy approaches on May 4, 2026. This represents the company's expansion into novel therapeutic modalities through strategic venture creation.
  • Valour BiocoreStrategic or Co-development Partner · 12 December 2025Completion of merger between Valerio Therapeutics and its subsidiary Valour Bio on December 12, 2025, following the proposed merger announced on October 31, 2025. This consolidation streamlines operations and strengthens the company's therapeutic development capabilities.

Scale indicators1 record

Recent moves8 records

Expansion highlights5 records

Onxeo competitors and assessment

Company assessment

Direct peers

  • Argenx: Commercial-stage biotech built on llama-derived VHH single-domain antibodies; the closest comparable to Valerio's V-Body sdAb platform, with multiple approved and late-stage autoimmune programs.
  • Molecular Partners: Develops DARPins and other small designed binding proteins for oncology; comparable to Valerio's use of ultra-small, fully synthetic single-domain scaffolds for targeted therapeutics.
  • Harbour BioMed: Operates a single-domain antibody (HBM7008 and others) platform spanning immuno-oncology and immunology; directly comparable in using sdAb-based therapeutics.
  • Genmab: Antibody platform company (Duobody, Hexabody) with multiple approved and partnered oncology assets; comparable partner-driven business model and focus on next-generation antibody engineering.
  • Pyxis Oncology: Clinical-stage developer of antibody-drug conjugates and immunotherapies for difficult-to-treat tumors; comparable ADC pipeline and oncology focus.

Emerging players

  • Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs); comparable as a small-cap ADC developer with platform technology.
  • Cellectis: Clinical-stage gene and cell therapy company working on allogeneic and in vivo cell therapy approaches; relevant peer for Valerio's newly launched InVimmune subsidiary.

Broad incumbents

  • ImmunoGen (AbbVie): Pioneer in ADC technology (now part of AbbVie following the 2024 acquisition); broader incumbent with approved ADCs and an established payload/linker franchise.
  • Daiichi Sankyo: Co-developer of Enhertu and Datroway with AstraZeneca; large incumbent in the ADC space that Valerio's chemistry platform ultimately competes with or partners alongside.
  • Sanofi (Ablynx): Acquired Ablynx, the originator of Nanobody/VHH therapeutics; the established large-pharma owner of the most clinically validated sdAb franchise (e.g., Cablivi).

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Onxeo social profiles

Digital presence

Onxeo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Onxeo leadership team

Management profile

Number of profiles

Profiles3 records

Onxeo subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Onxeo funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Onxeo M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Onxeo

What does Onxeo do?

Valerio Therapeutics (formerly Onxeo) develops precision-guided therapeutics through two integrated proprietary platforms: the V-Body Platform, based on ultra-small (~15 kDa) fully synthetic single-domain antibodies enabling deep tissue penetration and precise therapeutic delivery, and the Fully Integrated Chemistry Platform for drug conjugate development. The company advances candidates from preclinical research to clinical proof of concept in indications with high unmet medical need, then commercializes via strategic partnerships, co-development, and out-licensing.

Is Onxeo a public or private company?

Onxeo is a public company. It is classified as public and is currently operating.

When was Onxeo founded?

Onxeo was founded in 2005. It employs 11 to 50 people.

Where is Onxeo based?

Onxeo is headquartered in Villejuif, France, in the Europe region.

How does Onxeo make money?

One revenue line is on record: strategic partnerships and licensing.

Who are Onxeo's main competitors?

Direct peers on record are Argenx, Molecular Partners, Harbour BioMed, Genmab and Pyxis Oncology. Emerging players are Bolt Biotherapeutics and Cellectis. Broad incumbents are ImmunoGen (AbbVie), Daiichi Sankyo and Sanofi (Ablynx).

Does Onxeo have an API?

No public API is recorded for Onxeo.

What industry is Onxeo in?

Onxeo's product category is Precision-Guided Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAH, Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldOnxeo advances DDR agonist OX-425 towards IND filing for solid tumorsOnxeo SA expanded its pipeline with OX-425, an optimized compound of the OX-400 series from its proprietary Platon platform. The company is advancing this DDR agonist toward an IND filing for solid tumors.Business Wire BlogOnxeo Reports its Full-Year 2021 Financial Results and Announces Additional Financing of €12 MillionOnxeo reported a net loss of €5.9 million for the fiscal year 2021 and secured an additional €12 million in financing from existing shareholders Invus and Financière de la Montagne to extend its financial visibility until the second quarter of 2023. The company generated €4.1 million in revenues, primarily driven by non-recurring royalties from Biogen, while continuing clinical development of its lead candidate AsiDNA in collaboration with the Institut Curie.PharmiWeb.comOnxeo Reports its Full-Year 2021 Financial Results and Announces Additional Financing of €12 MillionOnxeo reported a net loss of €5.9 million for the fiscal year 2021 while securing an additional €12 million in financing from shareholders Invus and Financière de la Montagne to extend its financial runway into 2023. The company's revenues totaled €4.1 million, primarily driven by royalties from Biogen, as it continued clinical development of its lead candidate AsiDNA and preclinical work on OX400 compounds.BioSpaceOnxeo Continues to Strengthen its Board of DirectorsOnxeo appointed Bryan Giraudo as independent board member, replacing Thomas Hofstaetter after three mandates. Giraudo, COO and CFO of Gossamer Bio, brings US life sciences investment banking experience. The appointment strengthens Onxeo's international focus and supports its AsiDNA clinical program.GlobeNewswireOnxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare SectorOnxeo appointed Dr Robert L. Coleman and Dr Jacques Mallet as independent board members. Coleman is Chief Scientific Officer of US Oncology Network, and Mallet is a former Sanofi executive with 30 years in pharma. They will support Onxeo's development of AsiDNA and expansion into the U.S.GlobeNewswireOnxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the BoardOnxeo appointed Dr. Shefali Agarwal as Chairwoman of its Board of Directors, with Danièle Guyot-Caparros remaining as independent member and Audit Committee Chair. Agarwal, Chief Medical and Development Officer at Epizyme, brings experience from Tesaro and other biotech firms. The appointment marks a new stage in Onxeo's development, focusing on clinical demonstration of its DDR approach.GlobeNewswireOnxeo to Present New Preclinical Data at AACR 2021Onxeo will present preclinical data at AACR 2021 showing its drug AsiDNA prevents resistance to KRAS inhibitors emerging from drug-tolerant persister cells. The data also describes OX400 family molecules that interfere with PARP signaling and display immunomodulatory and metabolic effects.GlobeNewswireOnxeo Announces Enrollment of First Patient in Phase Ib/II Study RevocanOnxeo announced the first patient enrolled in the Revocan phase 1b/2 study, which tests AsiDNA™ added to niraparib for relapsed ovarian cancer. First results are expected in early 2021, with up to 26 patients planned. The study aims to prove AsiDNA™ reverses acquired resistance to PARP inhibitors.Business Wire BlogOnxeo S.A. : Publication of the 2019 Universal Registration DocumentOnxeo S.A. published its 2019 Universal Registration Document, filed with the French stock-market authority on April 27, 2020. The document includes the annual financial report, corporate governance report, and auditors' reports, and highlights its AsiDNA and OX401 drug candidates.GlobeNewswireOnxeo to Present Next-Generation PARP Inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020Onxeo announced that its Chief Scientific Officer will present OX401, a next-generation PARP inhibitor, at the PARP & DDR Inhibitors Summit 2020 in Boston on January 29-30, 2020. The compound is optimized for PARP inhibition and STING response, aiming to bypass resistance and HR deficiency. It is undergoing preclinical proof-of-concept studies.